Search Results - "Zhukova, L. G."

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists by Zhukova, L. G., Mukhina, M. A.

“…The use of CDK4/6 inhibitors in combination with endocrine therapy (aromatase inhibitors and fulvestrant) allowed us to radically change our understanding of…”
Get full text

Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) by Zhukova, L. G., Smolin, S. A.

“…Up until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment…”
Get full text

Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation by Zhuravleva, M. V., Kokushkin, K. A., Luchinin, E. A., Luchinina, E. V., Kameneva, T. R., Kuznetsova, E. V., Krysanova, V. S., Makarova, E. V., Zhukova, L. G.

“…Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human…”
Get full text

The use of digital radiography in the morphological evaluation of tumor response to neoadjuvant treatment of breast cancer by Telezhnikova, I M, Zhukova, L G, Khomeriki, S G, Abduraimov, A B, Maksimov, N A, Setdikova, G R

“…To optimize the morphological assessment of tumor response to neoadjuvant therapy in breast cancer. A retro- and prospective cohort study was conducted. The…”
Get more information

Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy by Vasyuk, Yu. A., Shupenina, E. Y., Novosel, E. O., Vyzhigin, D. A., Nosova, A. G., Zhukova, L. G., Filonenko, D. A., Khatkova, E. I.

“…Aim . To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an…”
Get full text

Early and late postoperative complications of robot-assisted radical subcutaneous mastectomy with endoprosthesis by Kvetenadze, G. E. , Shivilov, E. V., Arslanov, Kh. S., Zhukova, L.  G., Khatkov,  I.  E.

“…Over the past two decades, the surgical treatment of breast cancer (BC) has changed from standard radical mastectomies to organ-preserving and reconstructive…”
Get full text

Multiple primary malignant neoplasms of the mouth and oropharynx by Kropotov, M. A., Yakovleva, L. P., Zhukova, L. G., Agabekyan, G. O., Khodos, A. V., Safarov, D. A., Gavrishchuk, P. A., Tigrov, M. S., Vyalov, A. S.

“…Introduction . Probability of development of multiple primary tumors in patients who received treatment due to head and neck cancers varies between 5.6 and…”
Get full text

Olaparib in the metastatic HER2-negative breast cancer setting by Zhukova, L. G., Khatkova, E. I., Ganshina, I. P., Kolyadina, I. V., Lubennikova, E. V.

“…Understanding of cancer biology is at the cornerstone of design of new and effective treatment strategies. Identification of molecular drivers of tumor growth…”
Get full text

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice by Filonenko, D. A., Ibragimova, T. M., Polshina, N. I., Belogurova, A. V., Khatkova, E. I., Arutiunian, E. A., Volkova, E. I., Zhukova, L. G.

“…Introduction . Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast…”
Get full text

Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role? by Gordeeva, O. O., Zhukova, L. G., Kolyadina, I. V., Ganshina, I. P.

“…Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to…”
Get full text

ASSOCIATION OF NKT- AND ACTIVATED CD25+ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS by Chertkova, A. I., Slavina, E. G., Zabotina, T. N., Kadagidze, Z. G., Shoua, E. K., Gordeeva, O. O., Kolyadina, I. V., Zhukova, L. G., Gan’shina, I. P., Meshcheryakov, A. A.

“…Background . We previously found that a decrease in the number of NKT cells and activated CD 25+ peripheral blood lymphocytes (PBLs) before neoadjuvant…”
Get full text

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case by L. G. Zhukova, K. S. Bardovskaya, E. V. Lubennikova, I. R. Suslova

“…Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the…”
Get full text

Ribociclib in 1st line HR+ breast cancer treatment by Zhukova, L G, Ganshina, I P, Gordeeva, O O, Lubennikova, E V

“…Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a…”
Get full text

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer by Gordeeva, O. O., Kolyadina, I. V., Zhukova, L. G., Ganshina, I. P., Vyshinskaya, G. V., Kazantseva, M. A., Sukhova, M. V., Ryabishina, O. E., Lubennikova, E. V., Filonenko, D. A., Chichikov, E. I., Polushkina, I. N., Borisova, E. I., Lud, A. N., Meshcheryakov, A. A.

“…Background . Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment…”
Get full text

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY by Chertkova, A. I., Slavina, E. G., Shoua, E. K., Zhukova, L. G., Okruzhnova, M. A., Nurtdinova, V. A., Borunova, A. A., Dzhgamadze, N. Т., Kadagidze, Z. G.

“…Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many…”
Get full text

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice by Zhukova, L. G., Khatkova, E. I., Feoklistova, P. S., Grechukhina, K. S., Smolin, S. A., Arutyunyan, E. A., Kolyago, E. M.

“…Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities…”
Get full text

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved? by Zhukova, L G, Ganshina, I P, Khatkova, E I, Tikhomirova, T E, Kondratyeva, O E

“…According to the results of the conducted studies in the early 2000’s, adjuvant trastuzumab for 1 year has been admitted the gold standard since 2006. However,…”
Get full text

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer by Semiglazova, T. Yu, Lubennikova, E. V., Bolotina, L. V., Orlova, R. V., Moiseenko, F. V., Avramenko, A. V., Artemeva, E. V., Borozdina, S. A., Vakhitova, A. A., Volkov, N. M., Ganshina, I. P., Dzhalilova, Sh. A., Zhukova, L. G., Kasparov, B. S., Kachmazov, A. A., Klimenko, V. V., Kornietskaya, A. I., Meshcheryakov, A. A., Paichadze, A. A., Poltoratsky, A. N., Ryabishina, O. E., Stepanova, M. L., Imyanitov, E. N

“…Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly…”
Get full text

The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case by D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, L. G. Zhukova

“…The survival of patients even with disseminated disease reached 7–8 years after introduction of imatinib and sunitinib for the treatment of gastrointestinal…”
Get full text

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia by N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko

“…Background. Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an…”
Get full text